
**CLAIMS**

What is claimed is:

1. A compound of structural Formula I:



(I)

or a salt ~~or ester~~ thereof, wherein:

m is chosen from 0, 1, 2, 3, and 4;

$R^1$ is a nitrogen-containing heterocycloalkyl or heteroaryl, either of which is optionally substituted with 1, 2, or 3 $R^5$ groups;

$R^2$ is H, or is chosen from alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which is optionally substituted with 1, 2, or 3 $R^6$ groups;

$R^3$ is chosen from aryl and heteroaryl, either of which is optionally substituted with 1, 2, or 3 $R^7$ groups;

each $R^4$ is independently chosen from hydrogen, alkyl, alkenyl, alkynyl, and cycloalkyl;

each $R^5$ is independently chosen from halogen, alkyl, alkenyl, alkynyl, hydroxy, amino, oxo, cyano, $COR^8$, $CONR^8R^9$, $COOR^8$, $NHCOR^8$, $NHCONR^8R^9$, $SOR^8$, $SO_2R^8$, $NHSO_2R^8$, and $SO_2NR^8R^9$;


each $R^6$ is independently chosen from hydrogen, halogen, alkyl, alkylsulfonylaryl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkoxy, haloaryl, alkoxyaryl, aryl, aryloxy, aralkyl, heterocycloalkyl, heteroaryl, alkylheteroaryl, heteroarylalkyl, cyano, alkoxy, alkoxyaryl, amino, alkylamino, dialkylamino, oxo, $COR^8$, $SO_2R^8$, $NHSO_2R^8$, $NHSO_2NHR^8$, $SO_2NR^8R^9$, $NHCOR^8$, $NHCONHR^8$, $CONHR^8$, and $CONR^8R^9$;

each $R^7$ is independently chosen from alkyl, amino, cyano, halo, and hydroxy; and

each $R^8$ and $R^9$ is independently chosen from hydrogen, aryl, and lower alkyl; or $R^8$ and $R^9$ may be taken together to form a nitrogen-containing heterocycloalkyl or heteroaryl ring, which is optionally substituted with lower alkyl.

2. The compound as recited in claim 1, or a salt ~~or ester~~ thereof, wherein $R^3$ is phenyl, and is optionally substituted with 1 or 2 $R^7$ groups, and $R^7$ is fluorine.

3. The compound as recited in claim 1, having structural Formula II:



(II)

or a salt ~~or ester~~ thereof, wherein:

$R^1$ is a nitrogen-containing heterocycloalkyl or heteroaryl, either of which is optionally substituted with 1, 2, or 3 $R^5$ groups;

$R^2$ is H, or is chosen from alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which is optionally substituted with 1, 2, or 3 $R^6$ groups;

each $R^4$ is independently chosen from hydrogen, alkyl, alkenyl, alkynyl, and cycloalkyl;

each $R^5$ is independently chosen from halogen, alkyl, alkenyl, alkynyl, hydroxy, amino, oxo, cyano, $COR^8$, $CONR^8R^9$, $COOR^8$, $NHCOR^8$, $NHCONR^8R^9$, $SOR^8$, $SO_2R^8$, $NHSO_2R^8$, and $SO_2NR^8R^9$;


each $R^6$ is independently chosen from hydrogen, halogen, alkyl, alkylsulfonylaryl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkoxy, haloaryl, alkoxyaryl, aryl, aryloxy, aralkyl, heterocycloalkyl, heteroaryl, alkylheteroaryl, heteroarylalkyl, cyano, alkoxy, alkoxyaryl, amino, alkylamino, dialkylamino, oxo, $COR^8$, $SO_2R^8$, $NHSO_2R^8$, $NHSO_2NHR^8$, $SO_2NR^8R^9$, $NHCOR^8$, $NHCONHR^8$, $CONHR^8$, and $CONR^8R^9$;

each $R^7$ is independently chosen from hydrogen, alkyl, amino, cyano, halo, and hydroxy; and


each $R^8$ and $R^9$ is independently chosen from hydrogen, aryl, and lower alkyl; or $R^8$ and $R^9$ may be taken together to form a nitrogen-containing heterocycloalkyl or heteroaryl ring, which is optionally substituted with lower alkyl.

4. The compound as recited in any one of claims 1 – 3, or a salt ~~or ester~~ thereof, wherein $R^4$ is hydrogen.

5. The compound as recited in claim 3, or a salt ~~or ester~~ thereof, wherein $R^1$ is chosen from:


, and , and is optionally substituted with 1, 2, or 3 $R^5$ groups, and each $R^5$ is independently chosen from halogen, alkyl, hydroxy, amino, oxo, cyano, $COR^8$, $CONR^8R^9$, $COOR^8$, $NHCOR^8$, $NHCONR^8R^9$, $SOR^8$, $SO_2R^8$, $NHSO_2R^8$, and $SO_2NR^8R^9$.


6. The compound as recited in claim 3, or a salt ~~or ester~~ thereof, wherein $R^1$, with substitution $R_5$ where appropriate, and further with substitutions $R^8$ and $R^9$ where appropriate, is chosen from:





7. The compound as recited in claim 3, or a salt ~~or ester~~ thereof, wherein $R^2$ is H.


8. The compound as recited in claim 1, wherein the structure is chosen from:






,






,



,


,



,


,



,

,

,

,




,




,




,




,









,



,



,


,

,

,

,

, and

, or a salt ~~or ester~~ thereof.

9. A compound as recited in Claim 1, or a salt ~~or ester~~ thereof, for use as a medicament.

~~10.~~ A compound as recited in Claim 1, or a salt ~~or ester~~ thereof, for use in the treatment of a KDM1A-mediated disease~~.~~

~~11.~~10. ~~The use as recited in claim 10, wherein the disease is~~ chosen from cancer, myeloid disease, and inflammatory disease.

~~12.~~11. The compound for use as recited in claim ~~11~~10, or a salt thereof, wherein the cancer is chosen from Ewing's sarcoma, multiple myeloma, T-cell luekemia,Wilm's tumor, small-cell lung cancer, bladder cancer, prostate cancer, breast cancer, head/ neck cancer, colon cancer, and ovarian cancer.

~~13.~~12. The compound for use as recited in claim ~~11~~10, or a salt thereof, wherein the myeloid disease is chosen from Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML), and Chronic Myelogenous Leukemia (CML).

~~14.~~13. The compound for use as recited in claim ~~11~~10, or a salt thereof, wherein the inflammatory disease is chosen from inflammatory bowel disease, rheumatoid arthritis, or systemic lupus erythematosus.

~~15.~~14. ~~-~~A compound as recited in Claim 1, or a salt ~~or ester~~ thereof; and another therapeutic agent, for use in the treatment of a KDM1A-mediated disease~~.~~ chosen from cancer, myeloid disease, and inflammatory disease.

~~16.~~15. The compound for use as recited in Claim ~~15~~14, or a salt thereof, wherein said other agent is chosen from a DNA methyltransferase inhibitor, a histone deacetylase inhibitor, a histone de-sumoylase inhibitor, a histone de-ubiquitinase inhibitor, a histone phosphatase inhibitor, an antisense RNA that inhibits the expression of other components of the protein complex bound at the DR site in the gamma globin promoter, a Klf1 inhibitor, an agent that inhibits expression of *KLF1*, a Bcl11a inhibitor, an agent that inhibits the expression of *BCL11A*, an agent that inhibits cell cycle progression, and an agent that induce differentiation in leukemic cells.

~~17. A compound as recited in claim 1, or a salt or ester thereof, for use in a method of treatment of a globin-mediated disease.~~

~~18.~~16. A pharmaceutical composition comprising a compound as recited in claim 1, or a salt ~~or ester~~ thereof, together with a pharmaceutically acceptable carrier.